Zizhen Zhang1, Yunfeng Shu1, Yun Diao2, Yang Du3, Lizhi Chen1, Ying Liu2, Biao Du4. 1. School of Pharmacy, Southwest Medical University, Luzhou Sichuan. 2. School of Pharmacy, North Sichuan Medical College, Nanchong Sichuan. 3. Department of Psychosomatic Medicine. 4. Department of Pharmacy, the Affiliated Three Gorges Hospital of Chongqing University, Chongqing, China.
Abstract
BACKGROUND: The objective of this study is to systematically evaluate the efficacy and safety of the calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant for the treatment of acute migraine. METHODS: Randomized controlled trials (RCTs) of ubrogepant for treatment of acute migraine were identified in PubMed, MEDLINE, EMBASE, and the Cochrane Library from database establishment to June 2020; we also searched ClinicalTrials.gov manually during the same period. Then, RevMan 5.3 software was used to perform a meta-analysis on each outcome measure. RESULTS: A total of 5 RCTs involving 4903 patients were included; there were 3358 cases in the ubrogepant group and 1545 cases in the placebo group. The meta-analysis showed the following results: at 2 hours postdose, the percentages of participants reporting pain relief and the absence of photophobia, nausea, and phonophobia were significantly higher in the ubrogepant group than in the placebo group (odds ratio [OR] = 1.71, 95%CI: 1.48-1.97, P < .00001; OR = 1.33, 95%CI: 1.22-1.45, P < .00001; OR = 1.07, 95%CI: 1.03-1.11, P = .0006; OR = 1.21, 95%CI: 1.14-1.28, P < .00001). The incidence of common adverse events was similar between the 2 groups (P > .05). CONCLUSION: Ubrogepant is effective and safe for the treatment of acute migraine. REGISTRATION NUMBER: PROSPERO CRD42019145286.
BACKGROUND: The objective of this study is to systematically evaluate the efficacy and safety of the calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant for the treatment of acute migraine. METHODS: Randomized controlled trials (RCTs) of ubrogepant for treatment of acute migraine were identified in PubMed, MEDLINE, EMBASE, and the Cochrane Library from database establishment to June 2020; we also searched ClinicalTrials.gov manually during the same period. Then, RevMan 5.3 software was used to perform a meta-analysis on each outcome measure. RESULTS: A total of 5 RCTs involving 4903 patients were included; there were 3358 cases in the ubrogepant group and 1545 cases in the placebo group. The meta-analysis showed the following results: at 2 hours postdose, the percentages of participants reporting pain relief and the absence of photophobia, nausea, and phonophobia were significantly higher in the ubrogepant group than in the placebo group (odds ratio [OR] = 1.71, 95%CI: 1.48-1.97, P < .00001; OR = 1.33, 95%CI: 1.22-1.45, P < .00001; OR = 1.07, 95%CI: 1.03-1.11, P = .0006; OR = 1.21, 95%CI: 1.14-1.28, P < .00001). The incidence of common adverse events was similar between the 2 groups (P > .05). CONCLUSION: Ubrogepant is effective and safe for the treatment of acute migraine. REGISTRATION NUMBER: PROSPERO CRD42019145286.
Authors: Saurabh Gupta; Suneet Mehrotra; Carlos M Villalón; Ingrid M Garrelds; René de Vries; Jorge P van Kats; Hari S Sharma; Pramod R Saxena; Antoinette Maassenvandenbrink Journal: Eur J Pharmacol Date: 2005-12-22 Impact factor: 4.432
Authors: Richard B Lipton; David W Dodick; Jessica Ailani; Kaifeng Lu; Michelle Finnegan; Armin Szegedi; Joel M Trugman Journal: JAMA Date: 2019-11-19 Impact factor: 56.272
Authors: Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman Journal: Physiol Rev Date: 2017-04 Impact factor: 37.312
Authors: Tiffini Voss; Richard B Lipton; David W Dodick; Nicole Dupre; Joy Yang Ge; Robert Bachman; Christopher Assaid; Sheena K Aurora; David Michelson Journal: Cephalalgia Date: 2016-06-06 Impact factor: 6.292
Authors: Peter J Goadsby; Stewart J Tepper; Paul B Watkins; Girma Ayele; Rosa Miceli; Matthew Butler; Lawrence Severt; Michelle Finnegan; Armin Szegedi; Joel M Trugman; Abhijeet Jakate Journal: Cephalalgia Date: 2019-09-19 Impact factor: 6.292